<DOC>
	<DOCNO>NCT01524289</DOCNO>
	<brief_summary>The objective study evaluate efficacy tolerability add anacetrapib ongoing statin therapy participant heterozygous familial hypercholesterolemia .</brief_summary>
	<brief_title>Study Assess Tolerability Efficacy Anacetrapib Co-administered With Statin Participants With Heterozygous Familial Hypercholesterolemia ( MK-0859-020 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Anacetrapib</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>If reproductive potential , must agree remain abstinent use ( partner use ) 2 acceptable method birth control duration study Diagnosed Heterozygous Familial Hypercholesterolemia ( HeFH ) Have treat optimal dose statin least 6 week Received treatment lowdensity lipoprotein ( LDL ) apheresis within 4 week screen expect undergo treatment LDL apheresis course study Homozygous familial hypercholesterolemia Severe chronic heart failure Uncontrolled hypertension Uncontrolled cardiac arrhythmia , myocardial infarction ( MI ) , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) , unstable angina , stroke within 3 month Uncontrolled endocrine metabolic disease know influence serum lipid lipoproteins Active chronic hepatobiliary , hepatic , gall bladder disease Pregnant breastfeeding , plan become pregnant study within 2 year stop study mediation History ileal bypass , gastric bypass , significant condition associate malabsorption Human immunodeficiency virus ( HIV ) positive History malignancy â‰¤5 year Donated blood product phlebotomy &gt; 300 mL within 8 week intend donate 250 mL blood product receive blood product within project duration study Currently take medication potent inhibitor inducer cytochrome P450 3A4 ( CYP3A ) ( include limit cyclosporine , systemic itraconazole ketoconazole , erythromycin , clarithromycin , telithromycin , nefazodone , protease inhibitor , carbamazepine , phenobarbital , phenytoin , rifabutin , rifampin , St John 's wort ) discontinue treatment &lt; 3 week prior Consumes 2 alcoholic drink per day Currently participate participate study investigational compound device within 3 month Receiving treatment systemic corticosteroid take systemic anabolic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>